{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:05:48Z","timestamp":1777863948896,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0289"],"award-info":[{"award-number":["P3-0289"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0289"],"award-info":[{"award-number":["P3-0289"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-024-00706-5","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:25:35Z","timestamp":1734528335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two recurrent pathogenic\/likely pathogenic variants in PALB2 account for half of PALB2 positive families in Slovenia"],"prefix":"10.1186","volume":"18","author":[{"given":"Vita Andreja","family":"Mesari\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Blatnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Drusany Stari\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Strojnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vida","family":"Stegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Hotujec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vita \u0160etraj\u010di\u010d","family":"Drago\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"\u0160kerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdjan","family":"Novakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","volume":"22","author":"NS Kapoor","year":"2015","unstructured":"Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, et al. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1\/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1\/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Ann Surg Oncol. 2015;22:3282\u20138.","journal-title":"Ann Surg Oncol"},{"key":"706_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165\u20137.","journal-title":"Nat Genet"},{"key":"706_CR3","first-page":"1969","volume":"23","author":"ER Woodward","year":"2021","unstructured":"Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, et al. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Sci. 2021;23:1969\u201376.","journal-title":"Genet Sci"},{"key":"706_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10549-019-05483-7","volume":"179","author":"Y Wu","year":"2020","unstructured":"Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, et al. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1\/2-negative breast cancer patients. Breast Cancer Res Treat. 2020;179:605\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"706_CR5","doi-asserted-by":"publisher","unstructured":"Kotnik U, Maver A, Peterlin B, Lovrecic L. Assessment of pathogenic variation in gynecologic cancer genes in a national cohort. Sci Rep. 2023;13:1\u20139. https:\/\/doi.org\/10.1038\/s41598-023-32397-8","DOI":"10.1038\/s41598-023-32397-8"},{"key":"706_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","volume":"161","author":"M Pritzlaff","year":"2017","unstructured":"Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat. 2017;161:575\u201386.","journal-title":"Breast Cancer Res Treat"},{"key":"706_CR7","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1111\/cas.14565","volume":"111","author":"Y Hu","year":"2020","unstructured":"Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1\/2 mutations in pancreatic cancer. Cancer Sci. 2020;111:3111\u201321.","journal-title":"Cancer Sci"},{"key":"706_CR8","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMra0802968","volume":"359","author":"WD Foulkes","year":"2008","unstructured":"Foulkes WD. Inherited Susceptibility to Common Cancers. N Engl J Med. 2008;359:2143\u201353.","journal-title":"N Engl J Med"},{"key":"706_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J Clin Oncol. 2020;38:674\u201385.","journal-title":"J Clin Oncol"},{"key":"706_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","volume":"137","author":"CS Walsh","year":"2015","unstructured":"Walsh CS. Two decades beyond BRCA1\/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy? Gynecol Oncol. 2015;137:343\u201350.","journal-title":"Gynecol Oncol"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201809172","volume":"10","author":"M Castroviejo-Bermejo","year":"2018","unstructured":"Castroviejo-Bermejo M, Cruz C, Llop\u2010Guevara A, Guti\u00e9rrez\u2010Enr\u00edquez S, Ducy M, Ibrahim YH, et al. A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10:1\u201316.","journal-title":"EMBO Mol Med"},{"key":"706_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. May 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"706_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14061434","volume":"14","author":"V Stegel","year":"2022","unstructured":"Stegel V, Blatnik A, \u0160kof E, Drago\u0161 V\u0160, Krajc M, Gregori\u010d B, et al. Real-World Data on Detection of Germline and Somatic Pathogenic\/Likely Pathogenic Variants in BRCA1\/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. Cancers (Basel). 2022;14:1\u201317.","journal-title":"Cancers (Basel)"},{"key":"706_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5535-2","volume":"19","author":"A Gornjec","year":"2019","unstructured":"Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, et al. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019;19:1\u201310.","journal-title":"BMC Cancer"},{"key":"706_CR15","doi-asserted-by":"crossref","unstructured":"Klan\u010dar G, Blatnik A, Drago\u0161 V\u0160, Vogri\u010d V, Stegel V, Blatnik O et al. A novel germline MLH1 in-frame deletion in a Slovenian lynch syndrome family associated with uncommon isolated PMS2 loss in tumor tissue. Genes (Basel). 2020;11.","DOI":"10.3390\/genes11030325"},{"key":"706_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282\u201391.","journal-title":"Hum Mutat"},{"key":"706_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT den Dunnen","year":"2016","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, Mcgowan-Jordan J, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37:564\u20139.","journal-title":"Hum Mutat"},{"key":"706_CR18","doi-asserted-by":"crossref","unstructured":"Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, et al. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Res Treat. 2016;160:121\u20139.","DOI":"10.1007\/s10549-016-3981-y"},{"key":"706_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/humu.20318","volume":"27","author":"M Clendenning","year":"2006","unstructured":"Clendenning M, Hampel H, LaJeunesse J, Lindblom A, Lockman J, Nilbert M, et al. Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat. 2006;27:490\u20135.","journal-title":"Hum Mutat"},{"key":"706_CR20","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6.","DOI":"10.1126\/scisignal.2004088"},{"key":"706_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"706_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384:440\u201351.","journal-title":"N Engl J Med"},{"key":"706_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-022-06620-5","volume":"2","author":"A Gonzalez","year":"2022","unstructured":"Gonzalez A, Del Greco F, Vargas-Roig L, Brun B, Tabares G, Mampel A, et al. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina. Breast Cancer Res Treat. 2022;2:403\u201312.","journal-title":"Breast Cancer Res Treat"},{"key":"706_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature05609","volume":"446","author":"H Erkko","year":"2007","unstructured":"Erkko H, Xia B, Nikkil\u00e4 J, Schleutker J, Syrj\u00e4koski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316\u20139.","journal-title":"Nature"},{"key":"706_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s10038-019-0612-6","volume":"64","author":"A Vagena","year":"2019","unstructured":"Vagena A, Papamentzelopoulou M, Kalfakakou D, Kollia P, Papadimitriou C, Psyrri A, et al. PALB2 c.2257C > T truncating variant is a Greek founder and is associated with high breast cancer risk. J Hum Genet. 2019;64:767\u201373.","journal-title":"J Hum Genet"},{"key":"706_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10689-013-9684-1","volume":"13","author":"M Noskowicz","year":"2014","unstructured":"Noskowicz M, Bogdanova N, Bermisheva M, Takhirova Z, Antonenkova N, Khusnutdinova E, et al. Prevalence of PALB2 mutation c.509-510delGA in unselected breast cancer patients from Central and Eastern Europe. Fam Cancer. 2014;13:137\u201342.","journal-title":"Fam Cancer"},{"key":"706_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12920-017-0251-8","volume":"10","author":"A Kluska","year":"2017","unstructured":"Kluska A, Balabas A, Piatkowska M, Czarny K, Paczkowska K, Nowakowska D, et al. PALB2 mutations in BRCA1\/2-mutation negative breast and ovarian cancer patients from Poland. BMC Med Genomics. 2017;10:2\u20137.","journal-title":"BMC Med Genomics"},{"key":"706_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jcp-2022-208461","volume":"76","author":"O Hamdan","year":"2022","unstructured":"Hamdan O, Nowak KM. Gene of the month: PALB2. J Clin Pathol. 2022;76:73\u20135.","journal-title":"J Clin Pathol"},{"key":"706_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylk\u00e4s K, Roberts J, et al. Breast-Cancer Risk in Families with Mutations in PALB2. N Engl J Med. 2014;371:497\u2013506.","journal-title":"N Engl J Med"},{"key":"706_CR30","first-page":"1001","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Featured Updates to the NCCN Guidelines. JNCCN J Natl Compr Cancer Netw. 2023;21:1001\u201310.","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"706_CR31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdq460","volume":"22","author":"O Lavie","year":"2011","unstructured":"Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, et al. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. Apr 2011;22:964\u20136.","journal-title":"Ann Oncol"},{"key":"706_CR32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10549-012-2050-4","volume":"Aug","author":"S Heidemann","year":"2012","unstructured":"Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, et al. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat. 2012;Aug:1229\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"706_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-2971-1","volume":"145","author":"AP Sokolenko","year":"2014","unstructured":"Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN\/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat. 2014;145:553\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"706_CR34","doi-asserted-by":"crossref","unstructured":"Hini\u0107 S, Van der Cybulski C, Vos JR, Schuurs-Hoeijmakers J, Brugnoletti F et al. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet Sci. 2024;26.","DOI":"10.1016\/j.gim.2024.101101"}],"updated-by":[{"DOI":"10.1186\/s40246-026-00960-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000}}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-024-00706-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:34:00Z","timestamp":1777527240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40246-024-00706-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1186\/s40246-024-00706-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4569442\/v1","asserted-by":"object"}]},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Abstract, Ethics Approval and family name and given name of Dr.Kristina Drusany Stari\u010d has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40246-026-00960-9","URL":"https:\/\/doi.org\/10.1186\/s40246-026-00960-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent. The present study was approved by the National Ethics Committee and the Institutional Ethics Committee of the Institute of Oncology Ljubljana (0120\u2013591\/2020\/3 on the 20th of January 2021). Research was conducted according to the 1975 Helsinki Declaration as revised in 1983 and the procedures used met the ethical standards of these bodies. The present study was approved by the National Ethics Committee and the Institutional Ethics Committee of the Institute of Oncology Ljubljana (0120-591\/2020\/3 on the 20th of January 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}